- £13.14m
- £13.42m
- £2.87m
TR-1
Brief: EMV Capital Appoints Anesh Patel As Group CFO
Portfolio Update
Interim Results and Investor Presentation
Brief: EMV Capital Announces Asset Purchase Agreement With Destiny Pharma
Asset Purchase Agreement with Destiny Pharma
Notice of Interim Results
TR-1
Notice of AGM and Annual Report & Accounts
Director/PDMR Shareholding
Preliminary results for the year ended 31 Dec 2024
TR-1
PDS: Q4 Results and Clinical Programs Update
PDS Biotech reaffirms guidance for clinical trial
ProAxsis: Status Update and Proposed Fundraise
TR-1
Grant of Share Options
TR-1
Close of Fundraising and Result of Retail Offer